AmmarSukariMD

PubMed

• 27 citations
  Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
  Alexander Y Deneka, Yasmine Baca, Ilya G Serebriiskii, Emmanuelle Nicolas, Mitchell I Parker
  Clinical Cancer Research. 2022-05-02
• 1 citations
  Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy.
  Sourat Darabi, Tolulope Adeyelu, Andrew Elliott, Ammar Sukari, Kurt Hodges
  Journal of the American College of Surgeons. 2024-07-01
• 1618 citations
  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a ...
  Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara
  Lancet. 2019-11-23

Journal Articles

• Role of F-BOX proteins in Cancer Cachexia and Muscle Wasting  
  A Sukari, I Muqbil, P Trilokia, PA Philip, A Azmi, Seminars in Cancer Biology, 1/1/2016
• Concurrent Chemoradiation Improves Survival in Hypopharyngeal Cancer  
  P.A. Paximadis, T. Kumar, G. Yoo, H.S. Lin, J. Jacobs, A. Sukari, Z. Kafri, W. Yoo, A. Konski, H. Kim, International Journal of Radiation Oncology*Biology*Physics, 1/1/2010

Books/Book Chapters

• Chemotherapy in head and neck cancers 
  Chapter: Targeting Oral Cancer 
  D. Burchhardt, A. SukariSpringer2015

Abstracts/Posters

• Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC)
  J Bauml, T Y. Seiwert, D G. P fister, F P. Worden, S V. Liu, J Gilbert, N F. Saba, J Weiss, L J. Wirth, A Sukari, H Kang, M K. Gibson, E Massarelli, S F Powell, A Meis..., J Clin Oncol, 1/1/2016
• Definitive concurrent chemoradiotherapy (CRT) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) using systemic dose carboplatin: A retrospec...
  M Nagasaka, M A. Zaki, M Issa, H E. Kim, J Abrams, A Sukari, Annual ASCO Meeting, 1/1/2016
• A phase 2 trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and...
  S Powell, S Liu, A Sukari, C Chung, J Bauml, R Haddad, C Gause, M Niewood, L Gammage, H Brown, A Meister, J Cheng, M Gitau, ASCO Annual Meeting, 1/1/2015
• A Randomized Phase II Trial of the MET inhibitor Tivantinib + Cetuximab Versus Cetuximab alone in Patients with Recurrent/Metastatic Head and Neck Cancer
  E Vokes, F Worden, D Adkins, J Bauman, D Lim, A Sukari, K Rao, S Wagner, K Curtis, B Gitlitz, K Price, J L Wade III, V Villaflor, J De Souza, T Karrison, W Stadler, T ..., ASCO Annual Meeting, 1/1/2015
• A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer
  E Vokes, F Worden, D Adkins, J Bauman, D Lim, A Sukari, K Rao, S Wagner, K Curtis, B Gitlitz, K Price, J Wade III, V Villaflor, J De Souza, T Karrison, W Stadler, T Se..., Annual ASCO Meeting, 1/1/2015
• KEYNOTE-055: a phase 2 trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed...
  S Powell, S Liu, A Sukari, C Chung, J Bauml, R Haddad, C Gause, M Niewood, L Gammage, H Brown, A Meister, J Cheng, M Gitau, Annual ASCO Meeting, 1/1/2015
• Multiplex testing of potentially ‘actionable’ alterations in small cell lung cancer (SCLC)
  S Gadgeel, A Bollig-Fischer, A Schwartz, A Wozniak, M Cote, A Sukari, Wei Chen, L Mantha, G Bepler, J Clin Oncol, 1/1/2014
• Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck
  A Jimeno, M Posner, J Weiss, L Wirth, N Saba, R Cohen, E Popa, A Argiris, K Grossmann, A Sukari, C Korth, D Wilson, T McClure, M Alimzhanov, S Pearsall, K Attie, M She..., J Clin Oncol, 1/1/2014
• 994PD – Clinical activity of the oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients with head & neck squamous cell carcinoma (HN-SCC)
  A. Mahipal, N. Y. Gabrail, A. Sukari, H. Mahaseth, M. Mau-Sorensen, S. Shacham, J. Saint-Martin, S. Friedlander, Y. Landesman, J. Ellis, E. Shacham, J. McCartney, T. M..., Ann Oncol, 1/1/2014
• Multiplex testing of potentially ‘actionable’ alterations in small cell lung cancer (SCLC)
  S Gadgeel, A Bollig-Fischer, A Schwartz, AWozniak, M Cote, A Sukari, W Chen, L Mantha, G Bepler, ASCO, 1/1/2014
• Multiplex testing of driver mutations in non-small cell lung cancer (NSCLCs) of African-American (AA) patients
  S Gadgeel, M Cote, A Schwartz, A Bollig-Fischer, S Land, A Wenzlaff, Wei Chen, A Wozniak, A Sukari, L Mantha, G Bepler, J Clin Oncol, 1/1/2013
• Radiographic parameters in predicting outcome of patients with nonsquamous non-small cell lung cancer (NSCLC) treated with bevacizumab
  M Kaufman, M Salem, H Aoun, G Kalemkerian, SKunz, S El-Refai, P Ranganath, A Sukari, S Gadgeel, A Wozniak, J Clin Oncol, 1/1/2013
• Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
  A Jimeno, L Wirth, M Posner, R Cohen, J Weiss, E Popa, N Saba, K Grossmann, A Sukari, E Cohen, A Argiris, C Condon, D Wilson, T McClure, M Alimzhanov, S Pearsall, K At..., J Clin Oncol, 1/1/2013
• A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC)
  P Goncalves, S Kummar, L Siu, A Hansen, P Savvides, A Sukari, J Chao, L Heilbrun, M Pilat, D Smith, L Casetta, S Boerner, P LoRusso, J Clin Oncol, 1/1/2013
• Association of the development of bone metastases with the development of brain metastases in patients with non-small cell lung cancer
  M Salem, P Elson, N Pennell, A Sukari, S El-Refai, K Ali, S Gadgeel, N Szerlip, A Wozniak, J Clin Oncol, 1/1/2013
• Methotrexate and cetuximab for metastatic advanced head and neck squamous cell carcinoma
  B. Atassi, G. Yoo, H, H. Kim, O. Kucuk, A. Sukari, J Clin Oncol, 1/1/2013
• Radiographic parameters in predicting outcome of patients with nonsquamous non-small cell lung cancer (NSCLC) treated with bevacizumab
  M R Kaufman, M E. Salem, H Aoun, G P Kalemkerian, SKunz, S El-Refai, PRanganath, A Sukari, S M. Gadgeel, A J. Wozniak, ASCO Annual Meeting, 1/1/2013
• Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
  A Jimeno, L Wirth, M Posner, R Cohen, J Weiss, E Popa, N Saba, K Grossmann, A Sukari, E Cohen, A Argiris, C Condon, D Wilson, T McClure, M Alimzhanov, S Pearsall, K At..., ASCO, 1/1/2013
• The impact of bevacizumab on the occurrence and recurrence of intracranial brain metastases in non-small cell lung cancer (NSCLC) patients
  M. E. Salem, N. Szerlip, N. A. Pennell, K. Ali, D. Altshuler, S. Taylor, A. Hallock, A. Sukari, S. M. Gadgeel, A. J. Wozniak, ASCO, 1/1/2012
• Frequency of Anaplastic Lymphoma Kinase (ALK) positive tumors in African-American (AA) NSCLC patients
  Shirish M. Gadgeel, Michele L. Cote, Gerold Bepler, Valerie Murphy, Agnes Malysa, Antoinette J. Wozniak, A. Sukari, Ann G. Schwartz, J Clin Oncol, 1/1/2012
• Methotrexate and cetuximab for metastatic advanced head and neck squamous cell carcinoma: A retrospective study
  B. Atassi, K. Alsibai, G. H. Yoo, H. Lin, G. Dyson, H. Kim, J. Jacobs, O. Kucuk, A. Sukari, ASCO annual meeting, 1/1/2012
• The impact of bevacizumab on the occurrence and recurrence of intracranial brain metastases in non-small cell lung cancer (NSCLC) patients
  M Salem, N Szerlip, N Pennell, K Ali, D Altshuler, S Taylor, A Hallock, A Sukari, S Gadgeel, A Wozniak, J Clin Oncol, 1/1/2012
• Influence of induction chemotherapy on patients’ compliance to radiotherapy in patients with locally advanced head and neck squamous cell carcinoma
  B. Atassi, O. Ozgursoy, G. H. Yoo, J. R. Jacobs, N. S. Bhatti, M. Mal, H. Kim, H. Lin, A. Sukari, J Clin Oncol, 1/1/2011
• Nodal maximum SUV on staging FDG-PET is predictive for distant metastasis of patients with squamous cell carcinoma of the head and neck treated with upfront neck disse...
  M. Christensen, P. Paximadis, G. Dyson, D. Kamdar, A. Sukari, H.S. Lin, G. Yoo, H. Kim, Radiological Society of North America (RSNA), Chicago, IL, 1/1/2011
• Influence of induction chemotherapy on patients’ compliance to radiotherapy in patients with locally advanced head and neck squamous cell carcinoma
  B. Atassi, O. Ozgursoy, G. H. Yoo, J. R. Jacobs, N. S. Bhatti, M. Mal, H. Kim, H. Lin, A. Sukari, ASCO, 1/1/2011
• Join now to see all

Lectures

• How Can We Predict Who Will Respond to Checkpoint Inhibitors? 
  Wayne State University - 1/19/2016
• The potential breakthrough in management of Head & Neck Cancers through checkpoint inhibitors 
  Wayne State University - 1/15/2016
• The Future of Oncology; Cancer Immunotherapy in Head & Neck Cancer 
  Petoskey, MI - 1/14/2016
• Head and Neck Malignancies 
  Wayne State University - 1/2/2016
• Preliminary results from KEYNOTE-055: pembrolizumab (MK-3475) after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC) 
  1/1/2016
• TKI’s and Thyroid Cancer 
  Wayne State University - 1/23/2015
• Immunotherapy and Head and Neck Cancers 
  Wayne State University - 1/17/2015
• NSCLC update 
  Gaziantep University, Turkey - 1/1/2014
• Lung cancer update for PCPs 
  1/1/2014
• Principles of Chemotherapy in the Head and Neck Cancers 
  Wayne State University - 1/1/2014
• CME event on Head and neck screening for the internist 
  Clearwater, FL - 1/1/2013
• Head and Neck Cancers 
  Wayne State University - 1/1/2012
• Chemotherapy in Head and Neck Cancers 
  Wayne State University - 1/1/2012
• American College of Physicians, Acquired Factor X deficiency with light chain Amyloidosis: (Case Report and literature review) 
  1/1/2002
• Join now to see all